Last reviewed · How we verify
TILs（Tumor Infiltrating Lymphocytes）
At a glance
| Generic name | TILs（Tumor Infiltrating Lymphocytes） |
|---|---|
| Sponsor | Shanghai OriginCell Therapeutics Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- TILs Plus Third-Generation EGFR-TKI Therapy for TKI-Resistant NSCLC (EARLY_PHASE1)
- TILs Therapy for Multiple Primary Early-Stage NSCLC (EARLY_PHASE1)
- Immune Mechanisms After Radiofrequency Ablation of Pulmonary Metastases From Colorectal Cancer Origin (NA)
- Correlation Between TILs and Blood Cell Counts in Triple Negative Breast Cancer Patients
- Phenotypic Characterization Tumor-infiltrating Lymphocytes at Diagnosis and After Chemotherapy in Ovarian Cancer (NA)
- Neoadjuvant Pembrolizumab (PHASE2)
- TNFα and IL-2 Coding Oncolytic Adenovirus TILT-123 With Lymphocyte-depleting Chemotherapy and TILs in the Treatment of Melanoma (PHASE1)
- LM103 in Phase IIa Clinical Trial for Adjuvant Treatment in Patients With Non-small Cell Lung Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: